Summary Psoriasis is a hyperproliferative skin disorder in which immune mechanisms are thought to play a role. Recently, cyclosporin A has been found effective to treat psoriasis. However, mechanisms of action of cyclosporin A in patients are not well understood. We investigated seven patients (6 males. 1 female, aged 29-58 years) with severe psoriasis, three of them associated with arthropathy. The patients were treated with cyclosporin A given twice daily in gelatine capsules. Four patients were given 5 mg/kg, the others received 2.5 mg/kg initially. Two of them were put on 5 mg/kg (after 4 and 12 weeks of treatment). Clinical evaluation before and during therapy was carried out using the Psoriasis Area and Severity Index (PASI). Patients were followed up for 6 and 15 months. Their cyclosporin A blood levels were adjusted by a monoclonal radioimmunoassay. In parallel, serum and urine neopterin levels were quantified by HPLC. Mean neopterin concentrations in patients prior to therapy were found only slightly higher (serum 6.5± 0.8 mmol/l) than in healthy controls. There was no correlation of neopterin values and the degree of PASIscore. Onset of cyclosporin A was paralleled by decreasing neopterin concentrations and improvement of the skin status. Decrease of cyclosporin A doses was accompanied by an increase of PASI and significantly decreasing neopterin levels. In patients with severe relapses of psoriasis after withdrawal of cyclosporin A, neopterin rose higher than pretreatment levels. In 6/7 patients PASI and neopterin levels were closely correlated.
[1]
J. Barron,et al.
Increased urine neopterin levels in psoriasis
,
1992,
The British journal of dermatology.
[2]
D. Fuchs,et al.
Neopterin and psoriasis
,
1991,
The Lancet.
[3]
V. Dixit,et al.
Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction.
,
1991,
Journal of dermatological science.
[4]
G. Rassner,et al.
Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations.
,
1990,
Archives of dermatology.
[5]
E. Werner,et al.
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection.
,
1988,
Immunology today.
[6]
D. Fuchs,et al.
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma
,
1984,
The Journal of experimental medicine.
[7]
E. Werner,et al.
Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1.
,
1989,
Journal of acquired immune deficiency syndromes.
[8]
E. Werner,et al.
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application.
,
1989,
Advances in clinical chemistry.